Research Center for Translational Medicine
East Hospital
No. 150 Jimo Road
Shanghai 200120

Filippo G. Giancotti

Filippo G. Giancotti, M.D., Ph.D.

Professor, Department of Cancer Biology

Scientific Director, David H. Koch Center for Applied Research of GU Cancers

UT M.D. Anderson Cancer Center

Houston, TX 77054


Professor and Scientific Director
Advanced Department of Cell Biology
David H.Koch Center for Applied Research of GU Cancers

UT M.D. Anderson Cancer Center
Houston, TX 77054 USA


Filippo Giancotti obtained his M.D. degree from the University of Torino School of Medicine in Italy in 1981, and his Ph.D. degree from the same University in 1987.  After performing postdoctoral studies at the Burnham Institute in La Jolla, CA from 1988 to 1991, he established his laboratory at NYU School of Medicine in New York in 1992. In 1996 he moved to Memorial Sloan Kettering Cancer Center, where he raised through the ranks and became Member with permanent tenure of the Sloan Kettering Institute for Cancer Research in 2001.  Giancotti and colleagues have led the way in the elucidation of integrin signaling and its role in cancer.  In addition, they have uncovered the mechanism by which Merlin/NF2 suppresses tumorigenesis.  The Giancotti laboratory currently studies the molecular basis of tumor initiation and progression to metastasis with emphasis on the role of adhesion signaling in these processes.

Selected publications:

  1.  Okada T*, Esposito I*, Sinha S*, Schiavon G, Lopez-Lago MA, Su W, Pratilas CA, Abele C, Hernandez J, Ohara M, Okada M, Viale, A, Heguy A, Sapino A, Seshan VE, Long S, Inghirami G, Rosen N, and Giancotti FG. Inactivation of the Rho-GTPase Rnd1 induces neoplastic conversion and EMT by activating Ras Signaling in aggressive subtypes of breast cancer. Nat. Cell Biol. 17:81-94 (2015) [Editor’s Choice in Science Signaling].
  2.  Li W, Cooper J, Zhou L, Yang C, Erdjument-Bromage H, Zagzag D, Snuderl M, Ladanyi M, Hanneman O, Zhou P, Karajannis M, and Giancotti FG. Merlin/NF2 loss-driven tumorigenesis linked to CRL4DCAF1-mediated inhibition of the Hippo pathway kinases Lats1 and 2 in the nucleus. Cancer Cell 26:48-60 (2014).
  3.  Giancotti FG. Mechanisms governing metastatic dormancy and reactivation. Cell 155:750-64 (2013) [Review Article].
  4.  Gao H, Chakraborty G, Lim AP, Mo Q, Decker M, Vonica A, Shen R, Brogi E, Brivanlou AH, and Giancotti FG. The BMP inhibitor Coco reactivates breast cancer cells at lung metastatic sites. Cell 150:764-779 (2012) [Research Watch in Cancer Discov.; Research Highlight in Nat. Rev. Cancer; Editor’s Choice in The Scientist; Recommended F1000].
  5.  Li W*, You L*, Cooper J, Schiavon G, Pepe-Caprio A, Zhou L, Ishii R, Giovannini M, Hanemann CO, Long SB, Erdjument-Bromage H, Zhou P, Tempst P, and Giancotti FG. Merlin/NF2 suppresses tumorigenesis by inhibiting the E3 ubiquitin ligase CRL4DCAF1 in the nucleus. Cell 140:477-490 (2010) [cover article; Must Read F1000].


*Equal Contribution

Home Institution Website:
E mail: